CN116134025A - 酰胺膦氧类衍生物及其制备方法和用途 - Google Patents

酰胺膦氧类衍生物及其制备方法和用途 Download PDF

Info

Publication number
CN116134025A
CN116134025A CN202180062252.5A CN202180062252A CN116134025A CN 116134025 A CN116134025 A CN 116134025A CN 202180062252 A CN202180062252 A CN 202180062252A CN 116134025 A CN116134025 A CN 116134025A
Authority
CN
China
Prior art keywords
group
alkyl
groups
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180062252.5A
Other languages
English (en)
Inventor
邱海波
翟文强
卢勇平
朱亚波
张斌浩
马玉涛
叶成
钱文建
胡泰山
陈磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hisun Pharmaceutical Co Ltd
Shanghai Aryl Pharmtech Co Ltd
Original Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Shanghai Aryl Pharmtech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharmaceutical Co Ltd, Shanghai Aryl Pharmtech Co Ltd filed Critical Zhejiang Hisun Pharmaceutical Co Ltd
Publication of CN116134025A publication Critical patent/CN116134025A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及酰胺膦氧类衍生物、其制备方法及其在医药上的应用。具体而言，本发明涉及一种通式(I)所示的酰胺膦氧类衍生物、其制备方法及其可药用的盐，以及它们作为治疗剂，特别是作为凝血因子XIa(FXIa)抑制剂的用途，其中通式(I)中的各取代基的定义与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN202180062252.5A 2020-09-17 2021-09-16 酰胺膦氧类衍生物及其制备方法和用途 Pending CN116134025A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010977842 2020-09-17
CN2020109778428 2020-09-17
PCT/CN2021/118761 WO2022057858A1 (zh) 2020-09-17 2021-09-16 酰胺膦氧类衍生物及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN116134025A true CN116134025A (zh) 2023-05-16

Family

ID=80776488

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180062252.5A Pending CN116134025A (zh) 2020-09-17 2021-09-16 酰胺膦氧类衍生物及其制备方法和用途

Country Status (2)

Country Link
CN (1) CN116134025A (zh)
WO (1) WO2022057858A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2020094156A1 (zh) * 2018-11-11 2020-05-14 上海海雁医药科技有限公司 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704382A (en) * 1985-07-29 1987-11-03 G. D. Searle & Co. Phenylpiperazine phosphonates
EP0424317A3 (en) * 1989-10-19 1991-09-25 Ciba-Geigy Ag Pyrimidines
US5208234A (en) * 1992-03-10 1993-05-04 E. R. Squibb & Sons, Inc. Substituted imidazole phosphonic and phosphinic acid derivatives
EP2038262B1 (en) * 2006-05-25 2014-11-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US10143681B2 (en) * 2016-08-22 2018-12-04 Merck Sharp & Dohme Corp. Factor XIa inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2020094156A1 (zh) * 2018-11-11 2020-05-14 上海海雁医药科技有限公司 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PETER FINKBEINER ET AL.: ""Phosphine Oxides from a Medicinal Chemist’s Perspective: Physicochemical and in Vitro Parameters Relevant for Drug Discovery"", 《J. MED. CHEM.》, vol. 63, 1 June 2020 (2020-06-01), pages 7081 - 7107, XP055912950, DOI: 10.1021/acs.jmedchem.0c00407 *

Also Published As

Publication number Publication date
WO2022057858A1 (zh) 2022-03-24

Similar Documents

Publication Publication Date Title
CN116113632A (zh) 杂环类衍生物、其制备方法及其医药上的用途
JP2020519606A (ja) アミノピリジン化合物ならびにその調製および使用のための方法
CZ285799B6 (cs) Indolové deriváty, způsob jejich výroby, jejich použití pro výrobu farmaceutických prostředků a farmaceutické prostředky s jejich obsahem
AP877A (en) Tetrahydroquinoline derivatives as EAA antagonists.
CN116323625A (zh) 杂环类衍生物、其制备方法及其医药上的用途
CN107200734B (zh) 奎宁环衍生物及其制备方法和用途
BE898123A (fr) Nouveaux dérivés d'acides 4-oxo-1, 4-dihydronicotinique, leurs sels, un procédé pour leur production et agents antibactériens les contenant.
KR102600391B1 (ko) 삼중고리형 화합물
AU2013276165B2 (en) Tricyclic compounds as KAT II inhibitors
CN107840826B (zh) 1h-吲唑类衍生物及其作为ido抑制剂的用途
NO321528B1 (no) Cykloalkyl-substituerte aminometylpyrrolidin-derivater, og antibakterielle midler inneholdende slike forbindelser
CN114907387B (zh) 嘧啶并吡咯类kras抑制剂及其制备方法与应用
JP2022501391A (ja) 細菌感染症の治療及び予防のための、置換ピリドインドール
CN116134025A (zh) 酰胺膦氧类衍生物及其制备方法和用途
CN117769556A (zh) 嘧啶并环类衍生物及其制备方法和用途
JP2021512942A (ja) トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびｍＧｌｕ５受容体のモジュレータとしてのそれらの使用
KR20230104614A (ko) 아세트아미도-페닐벤즈아미드 유도체 및 그의 사용 방법
CN109705015B (zh) 组蛋白去乙酰化酶抑制剂及其制备方法与用途
CN103153990B (zh) 新型吡啶基苯并噁嗪衍生物、包含其的药物组合物及其用途
JP2004269547A (ja) キノキサリンジオン類の製造方法
CN115028648B (zh) 三并环化合物及其药物组合物和应用
JP7333420B2 (ja) トリアゾロピリミジン化合物及びその塩、組成物と使用
CN113527261A (zh) 吡啶酮或嘧啶酮类衍生物及其制备方法和用途
TWI692476B (zh) 環丁基-咪唑啶酮化合物
KR101872645B1 (ko) 신규한 4-(아릴)-N-(3-알콕시퓨로[2,3-b]피라진-2-일)-피페라진-1-카복스아미드 유도체 및 이의 항증식 효과

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination